A medical technology company based in Rehovot, Israel, recently received approval by the European CE for Bladder EpiCheck, a process that drastically reduces the pain and expense for patients monitoring the aftereffects of bladder cancer.

“Nucleix looks for fragments of DNA that are shed from tumours, and uses them to identify where they are coming from, and whether they are cancerous or not,” Nucleix CEO Dr Opher Shapira told The Jerusalem Post, adding that the process is being adapted to screen for lung cancer as well.

Elsewhere, researchers at Tel Aviv University recently announced a new blood test to detect genetic disorders in foetuses as early as 11 weeks into pregnancy.